1
40
2
-
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
February 2020 List
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
Citation List Month
February 2020 List
URL Address
<a href="http://doi.org/10.1016/j.seizure.2019.12.006" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/j.seizure.2019.12.006</a>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Cannabis-based products for pediatric epilepsy: An updated systematic review
Publisher
An entity responsible for making the resource available
Seizure
Date
A point or period of time associated with an event in the lifecycle of the resource
2019
Subject
The topic of the resource
Cannabidiol; Efficacy; Living systematic review; Paediatric drug-resistant epilepsy; Safety; Seizure
Creator
An entity primarily responsible for making the resource
Elliott J; DeJean D; Clifford T; Coyle D; Potter B K; Skidmore B; Alexander C; Repetski A E; Shukla V; McCoy B; Wells G A
Description
An account of the resource
PURPOSE: To provide an up-to-date summary of the benefits and harms of cannabis-based products for epilepsy in children. METHODS: We updated our earlier systematic review, by searching for studies published up to May 2019. We included randomized controlled trials (RCTs) and non-randomized studies (NRS) involving cannabis-based products administered to children with epilepsy. Outcomes were seizure freedom, seizure frequency, quality of life, sleep, status epilepticus, death, gastrointestinal adverse events, and emergency room visits. RESULTS: Thirty-five studies, including four RCTs, have assessed the benefits and harms of cannabis-based products in pediatric epilepsy (12 since April 2018). All involved cannabis-based products as adjunctive treatment, and most involved cannabidiol. In the RCTs, there was no statistically significant difference between cannabidiol and placebo for seizure freedom (relative risk 6.77, 95 % confidence interval [CI] 0.36-128.38), quality of life (mean difference [MD] 0.6, 95 %CI -2.6 to 3.9), or sleep disruption (MD -0.3, 95 %CI -0.8 to 0.2). Data from both RCTs and NRS suggest that cannabidiol reduces seizure frequency and increases treatment response; however, there is an increased risk of gastrointestinal adverse events. CONCLUSION: Newly available evidence supports earlier findings that cannabidiol probably reduces the frequency of seizures among children with drug-resistant epilepsy. PROSPERO: CRD42018084755.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/j.seizure.2019.12.006" target="_blank" rel="noreferrer noopener">10.1016/j.seizure.2019.12.006</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).
2019
Alexander C
Cannabidiol
Clifford T
Coyle D
DeJean D
Efficacy
Elliott J
February 2020 List
Living systematic review
McCoy B
Paediatric drug-resistant epilepsy
Potter B K
Repetski A E
Safety
Seizure
Shukla V
Skidmore B
Wells G A
-
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
October 2018 List
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
Citation List Month
September 2018 List
URL Address
<a href="http://doi.org/10.1186/s13643-018-0761-2" target="_blank" rel="noreferrer noopener">http://doi.o rg/10.1186/s13643-018-0761-2</a>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Cannabis for pediatric epilepsy: protocol for a living systematic review.
Publisher
An entity responsible for making the resource available
Systematic reviews
Date
A point or period of time associated with an event in the lifecycle of the resource
2018
Subject
The topic of the resource
Cannabidiol; Cannabinoids; Cannabis; Efficacy; Living systematic review; Meta-analysis; Pediatric epilepsy; Safety; Seizure
Creator
An entity primarily responsible for making the resource
Elliott J; DeJean D; Clifford T; Coyle D; Potter B; Skidmore B; Alexander C; Repetski AE; McCoy B; Wells GA
Description
An account of the resource
BACKGROUND: Pediatric epilepsy, including treatment-resistant forms, has a major effect on the quality of life, morbidity, and mortality of affected children. Interest has been growing in the use of medical cannabis as a treatment for pediatric epilepsy, yet there has been no comprehensive review of the benefits and harms of cannabis use in this population. In this systematic review, we will search for, synthesize, and assess the published and gray literature in order to provide usable and relevant information to parents, clinicians, and policy makers. METHODS: We will perform a living systematic review of studies involving the use of cannabis to treat pediatric epilepsy. We will search the published and gray literature for studies involving children with any type of epilepsy taking any form of cannabis. Studies will be selected for inclusion by two independent reviewers. The primary outcome is seizure freedom. Secondary outcomes are seizure frequency, quality of life (child, caregiver), quality and quantity of sleep, status epilepticus, tonic-clonic seizures, death (all-cause, sudden unexpected death in epilepsy), gastrointestinal adverse events (diarrhea, vomiting), and visits to the emergency room. The quality of each included study will be assessed. If data are sufficient in quantity and sufficiently similar, we will conduct pairwise random-effects meta-analysis. We will repeat the literature search every 6 months to identify studies published after the previous search date. Sequential meta-analysis will be performed as necessary to update the review findings. DISCUSSION: Our review aims to provide a comprehensive and up-to-date summary of the available evidence to inform decisions about the use of cannabis in children with treatment-resistant epilepsy. The results of this review will be of use to parents, clinicians, and policy makers as they navigate this rapidly evolving area. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42018084755.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1186/s13643-018-0761-2" target="_blank" rel="noreferrer noopener">10.1186/s13643-018-0761-2</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).
2018
Alexander C
Cannabidiol
Cannabinoids
Cannabis
Clifford T
Coyle D
DeJean D
Efficacy
Elliott J
Living systematic review
McCoy B
Meta-Analysis
Pediatric epilepsy
Potter B
Repetski AE
Safety
Seizure
September 2018 List
Skidmore B
Systematic reviews
Wells GA